Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc. (ODTX) priced its initial public offering on May 8, 2026 at $18.00 per share, raising $279M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $849.1M. J.P. Morgan was lead-left underwriter, joined by TD Cowen, Cantor and Wedbush and others. Covington & Burling advised the company and Cooley advised the underwriters.

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, using immunobiology, medicinal and computational chemistry to drug key signaling nodes that drive disease. Its candidate OD-001 has shown proof-of-concept.

Status

IPO

Ticker

ODTX

Exchange

Nasdaq Capital Market

Priced

May 8, 2026

IPO price

$18.00

Raised

$279M

Market cap at IPO price

$849.1M

First filed

Jan 17, 2025

Underwriters

J.P. Morgan, TD Cowen, Cantor, Wedbush and Oppenheimer

Company counsel

Covington & Burling

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.